Study Debunks Pharmaceutical Industry’s Claims That Medicare Drug Price Negotiation Would Harm R&D - Retired Americans

Study Debunks Pharmaceutical Industry’s Claims That Medicare Drug Price Negotiation Would Harm R&D - Retired Americans

A new study by Bentley University debunks the pharmaceutical industry’s claims that the Medicare drug price negotiation law would harm innovation and research. Drug research and development (R&D) spending actually increased after it passed despite these assertions, according to the analysis. The study evaluated spending at 134 corporations and found that R&D spending surged from $211 billion to more than $247 billion after the law passed in 2022…